文献速递支持与姑息治疗

单价双特异性PD-1/CTLA4抗体MEDI5752的设计与疗效

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells.
PubMed 文献 · Cancer Discov · 2021-01-08

MEDI5752是一种单价双特异性抗体,设计用于抑制PD-1通路并在PD-1+活化T细胞上增强CTLA4阻断。临床前研究显示其优先饱和PD-1+ T细胞上的CTLA4,诱导PD-1内化降解,并在肿瘤中富集增强活性;两名晚期实体瘤患者中观察到部分缓解。

要点

  • MEDI5752优先饱和PD-1+ T细胞上的CTLA4,降低诱导IL2分泌所需剂量。
  • MEDI5752导致PD-1快速内化降解,不同于常规PD-1/CTLA4单抗。
  • 两名晚期实体瘤患者接受MEDI5752后观察到稳健的部分缓解。

核心结论

  • MEDI5752是一种新型免疫治疗药物,设计用于优先抑制PD-1+ T细胞上的CTLA4,与常规PD-1和CTLA4单抗联合策略相比具有差异化活性潜力。

研究设计与样本

  • 临床前研究结合两名晚期实体瘤患者的治疗观察,评估MEDI5752的体外特性、体内分布及抗肿瘤活性。

主要发现

  • MEDI5752优先饱和PD-1+ T细胞上的CTLA4而非PD-1- T细胞,降低诱导IL2分泌所需剂量。
  • MEDI5752导致PD-1快速内化降解,而常规PD-1/CTLA4单抗无此作用。
  • MEDI5752在体内优先定位并积累于肿瘤,与靶向PD-1和CTLA4的单抗联合相比活性增强。
  • 两名晚期实体瘤患者接受MEDI5752治疗后观察到稳健的部分缓解。

临床怎么用

  • MEDI5752代表一种理性设计的免疫治疗策略,通过将CTLA4抑制导向PD-1+ T细胞可能减少全身免疫相关不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent bispecific antibody designed to suppress the PD-1 pathway and provide modulated CTLA4 inhibition favoring enhanced blockade on PD-1+ activated T cells. We show that MEDI5752 preferentially saturates CTLA4 on PD-1+ T cells versus PD-1- T cells, reducing the dose required to elicit IL2 secretion. Unlike conventional PD-1/CTLA4 mAbs, MEDI5752 leads to the rapid internalization and degradation of PD-1. Moreover, we show that MEDI5752 preferentially localizes and accumulates in tumors providing enhanced activity when compared with a combination of mAbs targeting PD-1 and CTLA4 in vivo. Following treatment with MEDI5752, robust partial responses were observed in two patients with advanced solid tumors. MEDI5752 represents a novel immunotherapy engineered to preferentially inhibit CTLA4 on PD-1+ T cells. SIGNIFICANCE: The unique characteristics of MEDI5752 represent a novel immunotherapy engineered to direct CTLA4 inhibition to PD-1+ T cells with the potential for differentiated activity when compared with current conventional mAb combination strategies targeting PD-1 and CTLA4. This molecule therefore represents a step forward in the rational design of cancer immunotherapy.See related commentary by Burton and Tawbi, p. 1008.This article is highlighted in the In This Issue feature, p. 995.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Dovedi SJ, Elder MJ, Yang C, et al. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells. Cancer Discov. 2021. PMID: 33419761. doi:10.1158/2159-8290.CD-20-1445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。